author-photo

Ola Kleveland

Norwegian University of Science and Technology

15

Papers

286

Citations

Citation Trend

Filter By

Papers (12) Sort By

Journal Conference Others

Tocilizumab increases citrullinated histone 3 in non-ST segment elevation myocardial infarction.

2021
Show All
- Source
- Cite
- Save
Citations (0)
Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction.

2021 Journal of the American College of Cardiology
Show All
- Source
- Cite
- Save
Citations (17)
Interleukin-6 Receptor Inhibition in Acute St-Segment Elevation Myocardial Infarction: A Randomised Placebo-Controlled Trial

2020 Social Science Research Network
Show All
- Source
- Cite
- Save
Citations (0)
EFFECT OF A SINGLE DOSE OF THE INTERLEUKIN-6 RECEPTOR ANTAGONIST TOCILIZUMAB ON MARKERS OF NEUTROPHIL EXTRACELLULAR TRAPS IN PATIENTS WITH NON-ST ELEVATION MYOCARDIAL INFARCTION

2020 Journal of the American College of Cardiology
Show All
- Source
- Cite
- Save
Citations (0)
Novel Insights Into the Effects of Interleukin 6 Antagonism in Non-ST-Segment-Elevation Myocardial Infarction Employing the SOMAscan Proteomics Platform.

2020 Journal of the American Heart Association
Show All
- Source
- Cite
- Save
Citations (3)
Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI)

2019
Show All
- Source
- Cite
- Save
Citations (21)
Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction

2019 International Journal of Cardiology
Show All
- Source
- Cite
- Save
Citations (6)
Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction

2018 International Journal of Cardiology
Show All
- Source
- Cite
- Save
Citations (14)
IL-6 receptor inhibition by tocilizumab attenuated expression of C5a receptor 1 and 2 in non-ST-elevation myocardial infarction.

2018 Frontiers in Immunology
Show All
- Source
- Cite
- Save
Citations (12)
The IL-6 receptor inhibitor tocilizumab attenuated expression of C5a receptor 1 and 2 in patients with myocardial infarction

2017 Molecular Immunology
Show All
- Source
- Cite
- Save
Citations (0)